DiversimAb™ Mouse Technology

Enhanced Epitopic Diversity for Your Most Challenging Targets

The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.

mice diversimab

 

Our platform is commonly used for generating various types of antibodies

It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.

Therapeutic and reagent antibodies 

Antibodies with customized cross-reactivity 

Highly specific antibodies

Potent antibodies 

Comparing Antibody Titers from DiversimAb™ and Balb/c Mice

We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.

immune

 

Enhanced Epitopic Diversity for Your Most Challenging Targets

The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.

mice diversimab

 

Our platform is commonly used for generating various types of antibodies

It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.

Therapeutic and reagent antibodies 

Antibodies with customized cross-reactivity 

Highly specific antibodies

Potent antibodies 

Comparing Antibody Titers from DiversimAb™ and Balb/c Mice

We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.

immune

 

VORTEILE

A Different Discovery Experience with DiversimAb™

Entdecken Sie mehr mit einer umfassenden Suite von Tools und Dienstleistungen für die Entwicklung und Optimierung von Antikörpern. Unsere TAO-Plattform bietet die wissenschaftliche Expertise unserer Antikörperingenieure mit innovativen Technologien, um Ihre biologische Identifizierung und Entwicklung zu beschleunigen.

Verbesserte Antikörpervielfalt

DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.

 

Difficult, High-Homology Epitope Targeting

Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.

Purpose-Built and Rapid Immunization Strategies for Tough Targets

Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.

Royalty-Free Use

Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.

A Different Discovery Experience with DiversimAb™

Entdecken Sie mehr mit einer umfassenden Suite von Tools und Dienstleistungen für die Entwicklung und Optimierung von Antikörpern. Unsere TAO-Plattform bietet die wissenschaftliche Expertise unserer Antikörperingenieure mit innovativen Technologien, um Ihre biologische Identifizierung und Entwicklung zu beschleunigen.

Verbesserte Antikörpervielfalt

DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.

 

Difficult, High-Homology Epitope Targeting

Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.

Purpose-Built and Rapid Immunization Strategies for Tough Targets

Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.

Royalty-Free Use

Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.

TECHNISCHE RESSOURCEN

Technische Ressourcen

DiversimAb™ Case Studies

Case studies Biopharma

Download the case study

DiversimAb™  Mouse for Antibody Discovery

Service SheetBiopharma

Download the service sheet

Technische Ressourcen

DiversimAb™ Case Studies

Case studies Biopharma

Download the case study

DiversimAb™  Mouse for Antibody Discovery

Service SheetBiopharma

Download the service sheet

Mehr erfahren

Der Goldstandard von Twist in der Antikörperidentifizierung

ProduktblattAntikörper

Produktblatt herunterladen

Optimierung und Entwicklung von Antikörpern

PosterBiopharma

Poster herunterladen

Twist Express Antikörper-Produktion

ProduktblattBiopharma

Twist Express Antikörper-Produktion

Charakterisierung und Entwicklungsfähigkeit von Antikörpern

WebinarBiopharma

Präsentation anzeigen

Kontakt

Antikörper-Enthusiasten stehen bereit und würden gerne mehr über Ihren Forschungsbedarf erfahren. Wir begrüßen schwierige Targets!

Powered by Translations.com GlobalLink Web Software